Maturitas, Journal Year: 2024, Volume and Issue: 193, P. 108170 - 108170
Published: Dec. 9, 2024
Language: Английский
Diseases, Journal Year: 2025, Volume and Issue: 13(1), P. 7 - 7
Published: Jan. 2, 2025
Urinary stones (urolithiasis) have been categorized as kidney (renal calculus), ureteric (ureteral calculus and ureterolith), bladder (bladder urethral (urethral calculus); however, the mechanisms underlying their promotion related injuries in glomerular tubular cells remain unclear. Although lifestyle-related diseases (LSRDs) such hyperglycemia, type 2 diabetic mellitus, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, cardiovascular disease are risk factors for urolithiasis, Recently, heat shock protein 90 (HSP90) on membrane of HK-2 human proximal epithelium has associated with adhesion urinary cytotoxicity. Further, HSP90 pancreatic breast can be modified by various advanced glycation end-products (AGEs), thus affecting function. Hypothesis 1: We hypothesized that HSP90s on/in types AGEs, they may affect functions it a key to reveal LSRDs urolithiasis. 2: considered possibility Japanese traditional medicines urolithiasis inhibit AGE generation. Of Choreito Urocalun (the extract Quercus salicina Blume/Quercus stenophylla Makino) used clinic, is Kampo medicine, while characteristic medicine. As contains quercetin, hesperidin, p-hydroxy cinnamic acid, which generation, we generation AGE-modified cells.
Language: Английский
Citations
1
Journal of Basic and Clinical Physiology and Pharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 13, 2025
Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder marked by repeated episodes of partial or complete upper airway obstruction during sleep, which leads to intermittent hypoxia and fragmented sleep. These disruptions negatively impact cardiovascular health, metabolic function, overall quality life. Obesity major modifiable risk factor for OSA, as it contributes both anatomical physiological mechanisms that increase the likelihood collapse While continuous positive pressure (CPAP) therapy remains gold standard OSA treatment, its limitations - particularly issues with patient adherence underscore need alternative adjunct therapeutic options. One such option use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are widely recognized their ability reduce body weight improve health. Emerging evidence suggests GLP-1 RAs may offer benefits in managing addressing obesity, key contributor condition. This narrative review seeks explore role treatment evaluating efficacy reducing severity discussing broader clinical implications future research practice.
Language: Английский
Citations
1
JAMA Otolaryngology–Head & Neck Surgery, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 2, 2025
This Viewpoint examines the potential role of neoadjuvant and adjuvant glucagon-like peptide–1 (GLP-1) receptor agonist therapy in improving surgical outcomes for patients with obstructive sleep apnea obesity.
Language: Английский
Citations
0
Cardiology in Review, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 14, 2025
Obstructive sleep apnea (OSA), a highly prevalent and serious disorder with significant complications, causes considerable daytime nighttime symptoms as well long-term consequences is yet an underdiagnosed inadequately treated condition. Patients OSA undergo frequent awakenings during the cycle find it impossible to get restorative sleep. Individuals are extremely fatigued, sleepy, irritable throughout day. Reduced exercise performance physical activity contribute decrease in energy metabolism weight gain. Those this population may experience decreased motivation, which could result depressive symptoms. The abrupt drops oxygen levels profound spikes blood pressure strain cardiovascular system. Given its close tie major risk factors, linked various diseases, including coronary artery disease, cardiac arrhythmia, poorly controlled pressure, heart failure, stroke. Continuous positive airway effective tried-trusted approach for symptom relief improving quality of life. Despite benefits, patients struggle compliance often go untreated because discomfort perceived inconvenience using these machines. One other explanation be lack awareness, comprehensive data, extensive research on effects metabolic complications caused by OSA. current standard treatment OSA, adequate greatly reduces morbidity. Nevertheless, disorders continue susceptible detrimental clinical consequences, even therapy available. In summary, continuous has indirect potential affect outcomes, but further studies should done address issues patient adherence.
Language: Английский
Citations
0
Médecine des Maladies Métaboliques, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Citations
0
Peptides, Journal Year: 2025, Volume and Issue: 187, P. 171380 - 171380
Published: March 11, 2025
Recent studies with peptide-based incretin herapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and dual tirzepatide that engages receptors for GLP-1 glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials 'real-world' confirmed marked glucose-lowering weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young elderly individuals without diabetes and/or overweight or obesity. also protections against development progression cardiovascular renal diseases are additive to benefits conferred by improved control blood glucose body weight. Emerging evidence suggests therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea possibly degenerative bone disorders cognitive decline. New incretin-based peptide in a long-acting glucagon (LY3324954), GLP-1/glucagon agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon (retatrutide, efocipegtrutide), combination amylin analogue cagrilintide (CagriSema), unimolecular GLP-1/amylin (amycretin), GIP antibody agonism (MariTide). The creation multi-targeting synthetic peptides provides opportunities management type 2 obesity as well new therapeutic approaches an expanding list associated co-morbidities. aim review is acquaint reader developments field from 2023 present (February 2025).
Language: Английский
Citations
0
Apollo Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: April 12, 2025
Diabetes and obstructive sleep apnoea (OSA) are interconnected chronic conditions. The increasing prevalence of obesity drives the pathogenesis these interrelated disorders. OSA, characterised by nocturnal hypoxia resulting from recurrent episodes upper airway obstruction during sleep, is common in individuals with type 2 diabetes mellitus (T2DM). At same time, T2DM increases risk OSA through mechanisms involving obesity, systemic inflammation, autonomic dysfunction. insulin resistance, impairs glucose tolerance, worsens glycaemic control. Management strategies should involve early screening for vice versa. Continuous positive pressure (CPAP) therapy improves sensitivity cardiovascular outcomes, though its impact on control remains inconsistent. Emerging evidence suggests that newer anti-obesity medications may reduce severity alongside improving metabolic parameters. Future research focus identifying molecular pathways linking diabetes, evaluating long-term CPAP benefits, optimising pharmacological approaches to improve outcomes both
Language: Английский
Citations
0
Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 2, 2024
Introduction Traditionally, obstructive sleep apnea (OSA) management has focused on continuous positive airway pressure therapy, oral appliances, and in some cases, surgical interventions. However, these treatments do not directly address the underlying metabolic issues contributing to OSA. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for type 2 diabetes management, have demonstrated substantial efficacy promoting weight.
Language: Английский
Citations
2
Maturitas, Journal Year: 2024, Volume and Issue: 193, P. 108170 - 108170
Published: Dec. 9, 2024
Language: Английский
Citations
1